Damien Choplain ...
  • Martial Descoutures

Galapagos : Stated ambitions still to be demonstrated

We are initiating coverage on Galapagos, with a Neutral recommendation and a target price of € 44. Unlike many of its peers in the biotech sector, Galapagos boasts a solid cash position thanks to its agreement with Gilead and already has a medicine on the market: Jyseleca. Conversely, the current stage of development of the group’s pipeline and its strategic shift into oncology justifies our caution. The POS applied to its point-of-care CAR-T platform will be adjusted upwards onl...
Galapagos NV

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.

Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Damien Choplain

Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch